Aveanna Healthcare Holdings Inc.
$11.01+$0.31 (+2.9%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.4B
- P/E
- 6.4x
- EV / EBITDA
- 10.3x
- Revenue
- $2.4B
- Net margin
- 9.2%
- ROCE
- 16.4%
Price chart
Technical chartScreen technicals →+32.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -13.6%
- 3M
- -15.1%
- 6M
- +43.4%
- 1Y
- +32.7%
- 5Y
- +49.2%
52-week range
Day change +$0.31 (+2.9%) from $10.70 to $11.01 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in AVAH, bought on each weekday since 2021.
News & filings
What Aveanna Healthcare Holdings filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernOperating profit was 1.8 times interest costs.
Strengths (1)
- Return on capital employed of 16.4%.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.
Read moreShow less
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers private duty nursing (PDN) services, which include in-home skilled nursing services to medically complex children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and non-clinical care, including support services and personal care services; and in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
- Sector
- Healthcare
- Shares outstanding
- 211.0M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.4B
- P/E
- 6.4x
- P/B
- 7.4x
- EV / EBITDA
- 10.3x
- EV / Sales
- 1.1x
- P/S
- 0.6x
- 52-week high
- $14.38
- 52-week low
- $6.22
Profitability
- Operating margin
- 10.7%
- Net margin
- 9.2%
- EBITDA margin
- 11.1%
- ROE
- 115.3%
- ROCE
- 16.4%
- ROIC
- 15.9%
- ROA
- 11.2%
- Asset turnover
- 1.21
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $2.4B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 20.2%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 10.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -2159.1%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $118.4M
Solvency
- Current ratio
- 1.32
- Debt / Equity
- 7.76
- Debt / Assets
- 0.75
- CFO / Net profit
- 0.56
- Cash / Market cap
- 13.4%
Where the revenue went
Of every $100 of FY2025 revenue, $9 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $1.6B |
| Revenue | Gross profit | $810.5M |
| Gross profit | Selling, general and administrative | $528.8M |
| Gross profit | Other operating expenses | $21.4M |
| Gross profit | Operating income | $260.3M |
| Operating income | Pretax income | $107.0M |
| Operating income | Interest and other expense | $153.3M |
| Pretax income | Net income | $107.0M |
| Tax benefit and other | Net income | $118.1M |
Revenue and net profit
Revenue grew 20.2% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $1.8B | -$662.0M |
| FY2023 | $1.9B | -$134.5M |
| FY2024 | $2.0B | -$10.9M |
| FY2025 | $2.4B | $225.0M |
Cash flows
FY2025: $125.9M from operations, $118.4M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$48.4M | -$60.4M |
| FY2023 | $22.7M | $13.9M |
| FY2024 | $32.6M | $26.3M |
| FY2025 | $125.9M | $118.4M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $2.4B+20.2%1Y
- EBITDA
- $269.4M+43.8%1Y
- Net profit
- $225.0M
- Cash from operations
- $125.9M+285.6%1Y
- Free cash flow
- $118.4M+349.9%1Y
- Revenue CAGR, 3Y
- 10.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $2.4B | $269.4M | $225.0M | $118.4M | 115.3% | +20.2% | -2159.1% |
Monthly returns
Month-by-month returns of AVAH across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $2.0B |
| Current assets | $560.2M |
| Non-current assets | $1.5B |
| Liabilities | $1.8B |
| Current liabilities | $424.5M |
| Non-current liabilities | $1.4B |
| Equity | $195.2M |
| Paid-in capital | $1.3B |
| Retained earnings | -$1.2B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; AVAH highlighted.
P/E against peers
AVAH trades at 6.4x earnings against a peer median of -15.3x.
Not shown (no positive earnings and no EV / Sales): MBX Biosciences, Inc., Maze Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Aveanna Healthcare Holdings Inc.AVAHthis company | $1.4B | 6.4x | 7.4x | 115.3% | 10.3x |
| STAAR Surgical CompanySTAA | $1.5B | -18.5x | 4.3x | -23.4% | -36.9x |
| Perrigo Company plcPRGO | $1.5B | -1.0x | 0.5x | -48.6% | -5.7x |
| NeoGenomics, Inc.NEO | $1.5B | -13.6x | 1.8x | -12.9% | -44.5x |
| MBX Biosciences, Inc.MBX | $1.5B | -16.9x | 4.0x | -23.6% | -14.3x |
| Monte Rosa Therapeutics, Inc.GLUE | $1.5B | -38.0x | 6.3x | -16.6% | -30.0x |
| Septerna, Inc.SEPN | $1.4B | -28.9x | 3.7x | -12.8% | -16.6x |
| Maze Therapeutics, Inc.MAZE | $1.4B | -10.7x | 4.0x | -36.9% | -8.8x |
| Healthcare Services Group, Inc.HCSG | $1.4B | 23.8x | 2.8x | 11.6% | 14.9x |
| Peer median | — | -15.3x | 3.8x | -20.0% | -15.5x |
Year-to-date ROI
AVAH since 1 January, against earlier years.
Historical volatility
AVAH's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 1.9% |
| FY2023 | 6.0% |
| FY2024 | 7.0% |
| FY2025 | 10.7% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $2.4B |
| Cost of revenueCost Of Revenue | $1.6B |
| Gross profitGross Profit | $810.5M |
| Operating expensesOperating Expense | $550.2M |
| Selling, general and administrativeSelling General And Administration | $528.8M |
| Other operating expensesOther Operating Expenses | $10.9M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $10.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $10.5M |
| Rent expense supplementalRent Expense Supplemental | $13.5M |
| Total expensesTotal Expenses | $2.2B |
| Operating incomeOperating Income | $260.3M |
| Interest and other | |
| Pretax incomePretax Income | $107.0M |
| TaxTax Provision | -$118.1M |
| Net incomeNet Income | $225.0M |
| Per share | |
| Supplementary | |
| Other lines |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $2.0B |
| Current assetsCurrent Assets | $560.2M |
| Non-current assetsTotal Non Current Assets | $1.5B |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.8B |
| Current liabilitiesCurrent Liabilities | $424.5M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $1.4B |
| EquityTotal Equity Gross Minority Interest | $195.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $125.9M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $125.9M |
| Net income, continuing operationsNet Income From Continuing Operations | $225.0M |
| Depreciation and amortisationDepreciation And Amortization | $28.2M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $28.2M |
| Depreciation | $28.2M |
| Stock-based compensationStock Based Compensation | $25.1M |
| Deferred taxDeferred Tax | -$143.0M |
| Deferred income taxDeferred Income Tax | -$143.0M |
| Operating gains and lossesOperating Gains Losses | $37.4M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $29.6M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $1.9M |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Asset impairmentAsset Impairment Charge | — |
| Change in working capitalChange In Working Capital | -$52.7M |
| Other non-cash itemsOther Non Cash Items | $5.8M |
| Investing cash flowInvesting Cash Flow | -$22.3M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$22.3M |
| Capital expenditureCapital Expenditure | -$7.4M |
| Purchase of PP&EPurchase Of PPE | -$7.4M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$7.4M |
| AcquisitionsPurchase Of Business | -$14.8M |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$14.8M |
| Purchase of investmentsPurchase Of Investment | — |
| Sale of investmentsSale Of Investment | — |
| Net investment purchases and salesNet Investment Purchase And Sale | — |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | $5.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $5.4M |
| Debt issuedIssuance Of Debt | $1.3B |
| Debt repaidRepayment Of Debt | -$1.3B |
| Net debt issuedNet Issuance Payments Of Debt | -$3.8M |
| Short-term debt issuedShort Term Debt Issuance | $0.00 |
| Short-term debt repaidShort Term Debt Payments | -$3.8M |
| Net short-term debt issuedNet Short Term Debt Issuance | -$3.8M |
| Long-term debt issuedLong Term Debt Issuance | $1.3B |
| Long-term debt repaidLong Term Debt Payments | -$1.3B |
| Net long-term debt issuedNet Long Term Debt Issuance | -$10.0k |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Stock options exercisedProceeds From Stock Option Exercised | $6.5M |
| Other financing chargesNet Other Financing Charges | $2.6M |
| Change in cashChanges In Cash | $109.0M |
| Cash at the start of the yearBeginning Cash Position | $84.3M |
| Cash at the end of the yearEnd Cash Position | $193.3M |
| Free cash flowFree Cash Flow | $118.4M |
| Supplemental |
Learn while you research
Academy chapters picked for Aveanna Healthcare Holdings Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 6.4 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Growth Investing20% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Leverage RatiosDebt/Equity of 7.76 is elevated, understand what that means for solvency.6 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read